Ophthalmology Drug Development Pipeline Review 2016: Which Companies are the Most Active? - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Ophthalmology Drug Development Pipeline Review, 2016" report to their offering.

The report provides comprehensive information on the pipeline development landscape for glaucoma, age-related macular degeneration, diabetic retinopathy, diabetic macular edema and keratoconjunctivitis sicca (dry eye), from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type.

A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope:

  • Which companies are the most active within the pipeline for ophthalmology?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have occurred in ophthalmology?

Reasons to buy:

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication.
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each.
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these.
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.

Key Topics Covered:

1. Tables & Figures

2. Introduction

3. Therapeutics Development by Stage

4. Therapeutics under Development by Companies

5. Therapeutics under Investigation by Universities/Institutes

6. Pipeline Products Glance

7. Products under Development by Companies

8. Products under Investigation by Universities/Institutes

9. Companies Involved in Therapeutics Development

10. Therapeutics Assessment

11. Recent Pipeline Updates

12. Dormant Projects

13. Discontinued Products

14. Product Development Milestones

15. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/lp8qsv/ophthalmology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Discovery, Optical

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Discovery, Optical